Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f2f1cdab2f9fc4016b9859e2e321ff7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T7-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01R13-516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K1-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2018-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0e03f2c761a7797174a3f2c380fd91d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2c427938f8c10ea7aaf7f954797032c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9c57c310040dc35014228479e2529ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c82638c915d74a0ad4a0ca6d886e49cc |
publicationDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2018264992-A1 |
titleOfInvention |
Combination therapies for treating cancer |
abstract |
The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death- 1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling. |
priorityDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |